KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Goodwill (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Goodwill for 5 consecutive years, with $47.8 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Goodwill changed 0.0% year-over-year to $47.8 million, compared with a TTM value of $47.8 million through Dec 2024, changed 0.0%, and an annual FY2024 reading of $47.8 million, changed 0.0% over the prior year.
  • Goodwill was $47.8 million for Q4 2024 at AbCellera Biologics, roughly flat from $47.8 million in the prior quarter.
  • Across five years, Goodwill topped out at $49.5 million in Q3 2021 and bottomed at $31.5 million in Q4 2020.
  • Average Goodwill over 5 years is $43.9 million, with a median of $47.8 million recorded in 2021.
  • The sharpest move saw Goodwill soared 51.77% in 2021, then dropped 3.34% in 2022.
  • Year by year, Goodwill stood at $31.5 million in 2020, then skyrocketed by 51.77% to $47.8 million in 2021, then changed by 0.0% to $47.8 million in 2022, then changed by 0.0% to $47.8 million in 2023, then changed by 0.0% to $47.8 million in 2024.
  • Business Quant data shows Goodwill for ABCL at $47.8 million in Q4 2024, $47.8 million in Q2 2024, and $47.8 million in Q4 2023.